Insulin-like Growth Factor-1 Receptor Inhibitor (IGF-1R) mAb

An insulin-like growth factor-1 receptor inhibitor monoclonal antibody is a targeted biologic agent engineered to bind to the extracellular domain of the insulin-like growth factor-1 receptor In clinical practice, the primary therapeutic application for this class is thyroid eye disease, where blocking receptor signaling on orbital fibroblasts reduces proptosis, inflammation, and diplopia, with additional historical and ongoing evaluation across various solid tumors and hematologic malignancies

An insulin-like growth factor-1 receptor inhibitor monoclonal antibody is a targeted biologic agent engineered to bind to the extracellular domain of the insulin-like growth factor-1 receptor By competitively blocking receptor activation and downregulating downstream signaling cascades—such as the PI3K/Akt pathway—these antibodies suppress pathological tissue remodeling, inflammation, and abnormal cell proliferation In clinical practice, the primary therapeutic application for this class is thyr...

By competitively blocking receptor activation and downregulating downstream signaling cascades—such as the PI3K/Akt pathway—these antibodies suppress pathological tissue remodeling, inflammation, and abnormal cell proliferation In clinical practice, the primary therapeutic application for this class is thyroid eye disease, where blocking receptor signaling on orbital fibroblasts reduces proptosis, inflammation, and diplopia, with additional historical and ongoing evaluation across various solid ...